
    
      This is a Phase 1/Phase 2 study. The objectives are as follows:

        1. Phase 1/1b: Determine the safety of a fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg
           expanded with IL-7/IL-15 at 8 and 12-day manufacturing times in relapsed refractory
           B-cell non-Hodgkin lymphoma (NHL) followed by expansion cohorts.

        2. Phase 2:

             1. Determine the three-month complete response (CR) rate of CAR-20/19-T cells in
                Mantle Cell Lymphoma (MCL).

             2. Determine the feasibility of a flexible manufacturing process of CAR-20/19-T cells
                from patient apheresis products using the CliniMACSÂ® Prodigy Cell processing
                device.
    
  